PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Takara Bio Europe Introduces GMP-Grade Cellartis® MSC EV Wonder™ to Support Clinical-Scale Extracellular Vesicle Production

Takara Bio Europe announces the introduction of a Good Manufacturing Practice (GMP)-grade version of Cellartis® MSC EV Wonder™, its defined, xeno-free medium developed for the efficient and scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs). The addition of a GMP-grade version expands the Cellartis portfolio, supporting the transition from early-stage EV research towards clinical development and manufacturing applications.

MSC-derived EVs are gaining increasing attention as promising candidates for next-generation cell-free therapies, particularly in regenerative medicine, immunomodulation and drug delivery. However, translating EV-based approaches from laboratory research to clinical applications requires consistent production processes, reproducible product quality and suitable manufacturing materials.

Originally developed to address challenges in EV yield and reproducibility, Cellartis MSC EV Wonder has demonstrated up to a nine-fold increase in EV production compared with conventional DMEM while maintaining essential EV characteristics, including canonical CD marker expression, morphology and RNA profiles. Its defined, phenol red-free formulation shares the same basal medium as the Cellartis MSC Xeno-Free Culture System, facilitating a streamlined workflow from MSC expansion to EV production.

With the introduction of the GMP-grade version, Takara Bio Europe aims to further support developers seeking to establish robust and scalable MSC-EV manufacturing workflows. The availability of GMP-grade medium provides an additional option for organizations advancing EV-based applications towards clinical translation, where material quality, process consistency and manufacturing controls become increasingly important.

“As interest in extracellular vesicle-based therapeutics continues to grow, the need for reliable and scalable manufacturing solutions becomes increasingly important,” said Tarik Hadi, PhD, Senior Market Strategy Manager at Takara Bio Europe. “By expanding Cellartis MSC EV Wonder with a GMP-grade option, we are strengthening our support for developers working to bridge the gap between scientific discovery and clinical translation.”

The GMP-grade version of Cellartis MSC EV Wonder™ is scheduled for launch on 28 October 2026. Researchers and organizations interested in learning more about the medium, its applications or technical specifications are encouraged to contact Takara Bio Europe at infoEU@takarabio.com.

About Takara Bio
Takara Bio Europe, a subsidiary of Takara Bio Inc., is a leading manufacturer and supplier of molecular and cellular biology reagents and services. Its portfolio supports applications including NGS, cloning, viral transduction, protein expression and purification, gene editing, nucleic acid extraction and stem cell research.

Key products include SMART NGS kits for DNA- and RNA-seq, Cellartis cell culture reagents, high-performance qPCR and PCR reagents, RT enzymes, and the innovative In-Fusion® cloning system. Takara Bio has recently expanded its capabilities to include spatial transcriptomics, complementing its existing expertise in NGS R&D, manufacturing and automation solutions for NGS and qPCR applications.

For more information, visit www.takarabio.com.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC